Products with Anti-platelet aggregation bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4818 | Piperolactam C |
| 1. Piperolactam C can inhibit the growth of the fungi Cladosporium sphaerospermum and C. cladosporioides. 2. Piperolactam C possesses anti-platelet aggregation activity in vitro. | |
| BCN4915 | Spiradine F |
| 1. Spiradine F can significantly inhibit platelet-activating factor(PAF)-induced platelet aggregation in a concentration-dependent manner. | |
| BCN4950 | Jujuboside B |
| Jujuboside B has antitumor activity and the underlying mechanism via induction of apoptosis and autophagy. It reduces vascular tension endothelium-dependently by increasing Ca2+Influx and activating endothelial nitric oxide synthase, it has pharmacological effects on improving endothelial dysfunction and treating vascular diseases. | |
| BCN4979 | Rhynchophylline |
| Rhynchophylline, a noncompetitive antagonist of the NMDA receptor, which has anti-inflammatory, anti-hypertension, cardiacprotective and neuroprotective activities. Rhynchophylline can markedly inhibit rabbit platelet aggregation induced by ADP or thrombin possibly by depressing the inflow of Ca2+ and the rise of the cytoplasmic free calcium level in platelet.Rhynchophylline can reduce the systolic blood pressure (SBP) of spontaneously hypertensive rats (SHR) significantly, decrease plasma Ang II, ADMA, and AT1R levels, and promote serum NO and NOS levels, which has the protection of vascular endothelial function. | |
| BCN5226 | Sideroxylin |
| 1. Sideroxylin can synergistically enhance the antimicrobial activity of the alkaloid berberine (also a constituent of H. canadensis) against Staphylococcus aureus by inhibition of the NorA multidrug resistance pump. | |
